HS
VERV

HighVista Strategies’s Verve Therapeutics VERV Stock Holding History

HighVista Strategies’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-35,600
Closed -$689K – 134
2022
Q4 		$689K Buy
+35,600
New +$943K 0.41% 68
2022
Q2 		– Sell
-14,073
Closed -$321K – 115
2022
Q1 		$321K Sell
14,073
-4,709
-25% -$135K 0.2% 86
2021
Q4 		$692K Hold
18,782
– – 0.55% 59
2021
Q3 		$883K Buy
+18,782
New +$1.1M 0.58% 57

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

HighVista Strategies's VERV Position: Q1 2023 in Review

HighVista Strategies sold out of Verve Therapeutics (VERV) in Q1 2023, closing a stake of 35,600 shares — an estimated $689K sold.

HighVista Strategies first reported a position in VERV in Q3 2021 and held it in 4 quarters. The position peaked at $883K in Q3 2021. 125 funds tracked by Wall St. Rank hold VERV as of Q1 2023.

  • HighVista Strategies reported no remaining Verve Therapeutics position as of Q1 2023 after selling out during the quarter.
  • HighVista Strategies sold 35,600 Verve Therapeutics shares in Q1 2023, an estimated $689K.
  • HighVista Strategies first reported a position in Verve Therapeutics in Q3 2021 and held it in 4 quarters.
  • HighVista Strategies's Verve Therapeutics position peaked at $883K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2023.

Based on HighVista Strategies's 13F filing for Q1 2023, filed 15 May 2023.